Risankizumab: First Global Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

30 citing papers in PubMed, 70 citations in OpenAlex.

1. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.The British journal of dermatology · 2021
   Trial
2. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.JAMA dermatology · 2020
   Trial
3. Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025
   Review
4. Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.Dermatology practical & conceptual · 2025
   Article
5. Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.Drugs · 2025
   Review
6. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis.Dermatology and therapy · 2024
   Article
7. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.Dermatology and therapy · 2024
   Review
8. New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.Pharmaceutics · 2024
   Review
9. Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Rheumatology and therapy · 2024
   Review
10. Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.Psoriasis (Auckland, N.Z.) · 2024
    Review
11. Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia.Cost effectiveness and resource allocation : C/E · 2023
    Article
12. A Transcriptome Array-Based Approach to Link SGLT-2 and Intrarenal Complement C5 Synthesis in Diabetic Nephropathy.International journal of molecular sciences · 2023
    Article
13. Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.Immunologic research · 2023
    Review
14. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.International journal of molecular sciences · 2023
    Review
15. Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021.Biomedicines · 2022
    Review
16. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period.Archives of dermatological research · 2022
    Article
17. Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia.Frontiers in oncology · 2022
    Review
18. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.Dermatologic therapy · 2022
    Article
19. [Successful treatment of generalized pustular psoriasis with certolizumab].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021
    Article
20. Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus.Journal of clinical medicine · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as